You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Pain management remains a significant unmet medical need. Anandamide is an endogenous marijuana-like ('endocannabinoid') molecule that plays important roles in the regulation of pain. Previous work has shown that endocannabinoid receptors located outside the central nervous system (CNS) exert a powerful regulatory control over pain initiation. Moreove ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Live-Cell Fluorescence Lifetime FRET Assays for HTS

    SBC: Fluorescence Innovations, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Novel LANCL2-based Anti-diabetic Compounds

    SBC: Biotherapeutics, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): About 28.3 million Americans have type II diabetes (T2D) and over 40.1% of middle-aged adults have prediabetes, a condition characterized by impaired glucose tolerance and insulin resistance. Current antidiabetic medications are effective in improving insulin sensitivity, but their chronic administration has significant side effects suc as cardiovascular compli ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A safer urinary catheter design to reduce catheter trauma and infections

    SBC: SAFE MEDICAL DESIGN, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): In today's device world, products must address soaring healthcare costs under the increased scrutiny of quality and safety. By addressing patient safety, we believe costs can be reduced and quality improved. Non-infectious urethral catheter related complications are one such patient safety problem the US and worldwide health care industry faces. Urethral c ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. A Luminal Vascular Coating to Prevent Intimal Hyperplasia Following Creation of a

    SBC: Symic Bio, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): This proposal addresses PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]). More than 20 million American adults (1 in 10) have some level of chronic kidney disease (CDC), with a growing incidence in the aging population. Nearly 400,000 ESRD patients receive some form of dialysis, with t ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced Nitric Oxide Release Bactericidal Urinary Catheters

    SBC: BIOCREDE INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): We propose a novel and competitive urinary tract silicone Foley catheter made from a proprietary polymeric formulation to effectively reduce catheter-associated urinary tract infections (CAUTI) via nitric oxide (NO) release. Preliminary studies show that the device will be able to: (1) continuously deliver NO at rates enough to maintain bactericidal properties ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS

    SBC: XFIBRA, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Activation of hepatic stellate cells (HSC) is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, HSC clearance by apoptosis may allow recovery from liver injury andreversal of liver fibrosis. There is full agreement among liver fibrosis experts that inhibiting o reversing HS activation (the therapeutic targ ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Reduction of Tunneled Dialysis Catheter Dysfunction Via Long Term Nitric Oxide Re

    SBC: BIOCREDE INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): We propose a novel and price competitive Tunneled Dialysis Catheter (TDC) made from a proprietary polymeric formulation to effectively reduce TDC dysfunction via long-term nitric oxide (NO) release, particularly duringthe period of AVF maturation in incident hemodialysis and TDC dependent patients. Preliminary studies with polymer materials used to prepare exis ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

    SBC: DYNAVAX TECHNOLOGIES CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation is unable to meet the needs of all patients afflicted with HF. We have shown that chronic liver injury involves the activation of Toll-like receptor 7 (TLR7) and TLR9. We further demonstrated that the ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Development of OCT Imaging Adapter for Interstitial Tissue Imaging

    SBC: WEST FACE MEDICAL DEVICES, INC.            Topic: NIBIB

    DESCRIPTION (provided by applicant): This Phase I STTR Grant Proposal requests 100,000 support for WestFace Medical Device to construct and test the WestFace Imaging Adaptor in conjunction with Ruikang K. Wang, PhD and his laboratory at the University ofWashington. Utilizing optical coherence tomography (OCT), the patented OCT Adaptor (USPTO Pats. # 7,682,089, # 8,057,107, #8,235,602) provides re ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government